Jane Street
SMMT icon

Jane Street’s Summit Therapeutics SMMT Stock Holding History

Jane Street’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-249,710
Closed -$6.06M – 11692
2025
Q2 		$5.31M Buy
249,710
+33,771
+16% +$770K ﹤0.01% 2907
2025
Q1 		$4.17M Buy
215,939
+80,839
+60% +$1.62M ﹤0.01% 3203
2024
Q4 		$2.41M Sell
135,100
-216,051
-62% -$4.19M ﹤0.01% 3789
2024
Q3 		$7.69M Buy
351,151
+163,306
+87% +$2.28M ﹤0.01% 2230
2024
Q2 		$1.47M Buy
187,845
+48,344
+35% +$261K ﹤0.01% 5052
2024
Q1 		$578K Buy
139,501
+30,134
+28% +$120K ﹤0.01% 6408
2023
Q4 		$285K Buy
+109,367
New +$225K ﹤0.01% 7666
2023
Q3 		– Sell
-21,399
Closed -$53.7K – 9326
2023
Q2 		$53.7K Sell
21,399
-393,692
-95% -$718K ﹤0.01% 8195
2023
Q1 		$726K Buy
415,091
+358,436
+633% +$978K ﹤0.01% 5645
2022
Q4 		$241K Buy
56,655
+36,396
+180% +$66.2K ﹤0.01% 7380
2022
Q3 		$24K Buy
+20,259
New +$22.9K ﹤0.01% 9156
2022
Q1 		– Sell
-12,143
Closed -$33K – 10967
2021
Q4 		$33K Buy
+12,143
New +$58.4K ﹤0.01% 9672

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jane Street's SMMT Position: Q3 2025 in Review

Jane Street sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 249,710 shares — an estimated $6.06M sold.

Jane Street first reported a position in SMMT in Q4 2021 and held it in 12 quarters. The position peaked at $7.69M in Q3 2024. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • Jane Street reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jane Street sold 249,710 Summit Therapeutics shares in Q3 2025, an estimated $6.06M.
  • Jane Street first reported a position in Summit Therapeutics in Q4 2021 and held it in 12 quarters.
  • Jane Street's Summit Therapeutics position peaked at $7.69M in Q3 2024.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Jane Street's 13F filing for Q3 2025, filed 14 Nov 2025.